Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of Sunday, July 26, 2026.
PE RATIO
N/A
Market Cap
$9.75B
PE Ratio
6.54
TTM Avg
9.06
3Y Avg
12.40
5Y Avg
12.29
Market Cap
$10.37B
PE Ratio
N/A
TTM Avg
33.48
3Y Avg
14.63
5Y Avg
25.08
Market Cap
$10.91B
PE Ratio
N/A
TTM Avg
225.66
3Y Avg
91.39
5Y Avg
72.20
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $7.47B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $7.31B | N/A | 60.92 | 60.92 | 60.92 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.50B | 51.81 | 27.92 | 27.92 | 15.54 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.27B | N/A | 61.96 | 88.48 | 88.48 |
| Henry Schein, Inc. (HSIC)vs › | $9.74B | 25.82 | 23.15 | 23.68 | 21.63 |
| Universal Health Services, Inc. (UHS)vs › | $9.75B | 6.54 | 9.06 | 12.40 | 12.29 |
| Molina Healthcare, Inc. (MOH)vs › | $10.31B | 1039.74 | 34.41 | 23.43 | 23.98 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 33.48 | 14.63 | 25.08 |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.91B | N/A | 225.66 | 91.39 | 72.20 |
| Bio-Techne Corporation (TECH)vs › | $11.21B | 103.77 | 108.18 | 74.79 | 74.41 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$42.69
Forward EPS (Est.)
$-0.34
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
